Legal Representation
Attorney
Mark Harrison
USPTO Deadlines
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 4, 2017 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Dec 4, 2017 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Apr 25, 2017 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 21, 2017 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Apr 21, 2017 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Apr 21, 2017 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 4, 2016 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 2, 2016 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 2, 2016 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 2, 2016 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 3, 2016 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 8, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 8, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 17, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 28, 2016 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 27, 2016 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 15, 2015 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | Loading... |
| Oct 15, 2015 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Oct 10, 2015 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 9, 2015 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and drug preparations for use in treatment of opioid overdose and addiction; Medicinal preparations for use in treatment of opioid overdose and addiction; Pharmaceutical and drug preparations for the treatment of substance use disorders, addiction, and overdose; Medicinal preparations for the treatment of substance use disorders, addiction, and overdose; Pharmaceutical preparations, namely, opioid antagonists; pharmaceutical preparations, namely, pharmaceuticals which contain the compound naloxone for use in the treatment of complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics; Pharmaceutical and drug preparations for use in complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005